Background. GNR bacteremia is common in the hospital environment. Drugresistance challenges thoughtful use of, and timely de-escalation to, regimens that limit carbapenem use. DBM accurately provides rapid identification of bacteremia pathogens, but lacks antibiotic susceptibility testing (AST) results to aid clinicians in refining therapy. We investigated whether integrating DBM identification and local BSI antibiogram data could be used to identify carbapenem-sparing regimens with predicted efficacy of ≥ 95% prior to traditional AST results.
